CH0329023102
CH0329023102
AC Immune SA
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 248.57M EUR | 236.64M EUR | 279.88M EUR | 319.47M EUR |
Enterprise Value | 182.28M EUR | 212.98M EUR | 265.01M EUR | 297.22M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 4.2x | -- | -- | -- |
Price to Sales | 14.2x | 13.52x | 75.6x | 123.68x |
Price to Book | 5.87x | 6.73x | 8.88x | 7.12x |
EV/Revenue | 10.41x | 12.16x | 71.59x | 115.07x |
EV/EBITDA | -4.29x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -13.33% | -14.8% | -18.22% | -21.96% |